Desmoid Tumors Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

 

Desmoid Tumors

A rare condition is the Desmoid Tumors. Fibroblasts are the cells that give rise to desmoid tumours. These cells can be found all over the body and play a critical part in wound healing in addition to provide structural support and protection. These tumours can happen at any age, although being most frequently discovered in women in their twenties and thirties. They may develop slowly or turn cancerous. Aggressive fibromatosis, however, might result in fatal consequences and other major issues. It is a specific type of illness that puts pressure on important organs like the intestines. There are some cases that are related to familial FAB polyposis, even if the majority of cases are not problematic. About 10% of people with Gardner's syndrome have Desmoid Tumors.

Global Desmoid Tumors Market is estimated to be valued at US$ 2,494.1 million in 2022 and is expected to exhibit a CAGR of 7.3% during the forecast period (2022-2030).

Drug development for the treatment of desmoid tumours is the primary focus of major Desmoid Tumors Market participants, and this strategy is anticipated to fuel market expansion over the coming years. For instance, in July 2022, Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, released encouraging interim results from Part A of the ongoing RINGSIDE Pivotal Phase 2/3 clinical study evaluating AL102 in desmoid tumours. The study is evaluating AL102 in patients with uncommon tumours and aggressive cancers.

AL102 is a potent and highly targeted GSI that is taken orally. Also, the existence of a desmoid tumour foundation, which provides funding for research into desmoid tumours, is anticipated to fuel market expansion in the nation over the coming years. For instance, the Desmoid Tumour Foundation of Canada (DFC) is a charitable organisation with the goal of sponsoring desmoid tumour research in Canada. DFC is committed to supporting Desmoid Tumors Market research and developing a treatment for this uncommon illness. DFC encourages research teams from various institutions to work together to discover treatments more quickly.

Drug Types:

·       Non-steroidal anti-inflammatory drugs (NSAIDs)

·       Targeted Therapy

·       Chemotherapy

·       Hormone Therapy

·       Others

Distribution Channel:

·       Hospital Pharmacy

·       Retail Pharmacy

·       Online Pharmacy

Major Companies involved are Horizon Therapeutics Plc, Strides Pharma Science Limited, Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Hikma Pharmaceuticals PLC,  Natco Pharma Ltd,  Lupin,  Zydus Lifesciences, Mylan N.V.,  Assertio Holdings, Inc.,  Mayne Pharma Group Limited, Alembic Pharmaceuticals Limited,  Aprazer, Ayala Pharmaceuticals,  SpringWorks Therapeutics, Inc.,  Iterion Therapeutics, Novartis AG, Apotex Inc.,  Bayer AG., Sun Pharmaceutical Industries Ltd, Dr. Reddy’s Laboratories Ltd., Endo International plc, Abbott, and Getwell Pharmaceuticals

Comments

Popular posts from this blog

Security Robot Market is Estimated To Witness High Growth Owing To Increasing Demand for Enhanced Surveillance

Monochloroacetic Acid (MCAA) Market Is Estimated To Witness High Growth Owing To Increasing Demand for Surfactants and Herbicides

The Ever-Evolving Landscape of the Scottish Whisky Market during the Forecast Period 2019-2027